Without question, evolving US tariff and trade policy was the story of the year in 2025, and how such policy will be implemented looms large. At the same time, the normal course of business in the bio/pharmaceutical industry—new drug approvals and the progression of pipelines, including new modalities—was also top of mind.

In a special episode of the DCAT Value Chain Insights’ Production to Prescription podcast, 2025: The Bio/Pharma Industry’s Year in Review, leading industry experts provide a snapshot view of key developments and trends across the bio/pharmaceutical manufacturing value chain in 2025 and those on the industry’s radar as we move to 2026.

Featured in this episode:

• The Global API Manufacturing Market, Julia Morilla, Associate Content Analyst, Cortellis Product Intelligence, Clarivate;
• The CDMO Market for Injectables, Ian Tzeng, Managing Director and Partner, L.E.K. Consulting, where he leads the firm’s Pharmaceutical Contract Services Practice;
• Blockbuster Contenders, Matthew Arnold, Principal Analyst and Content Strategist, Clarivate; and
• ADCs: Pipelines, Products & CDMO Growth, Gaurav Chaudhary, CEO, Roots Analysis.